Endothelin system-dependent cardiac remodeling in renovascular hypertension

Hypertension

Volumn 33, Issue 3, 1999, Pages 816-822

  Hocher, Berthold ^a,b   George, Ines ^b   Rebstock, Johannes ^a,b   Bauch, Alexandra ^b   Schwarz, Anja ^a,b   Neumayer, Hans H ^a   Bauer, Christian ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Endothelins; Hypertension; Remodeling; Renovascular

Indexed keywords

ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RENAL ARTERY; RENOVASCULAR HYPERTENSION;

EID: 0033066717     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.33.3.816     Document Type: Article

References (40)

1. Brilla CG. The cardiac structure-function relationship and the renin-angiotensin-aldosterone system in hypertension and heart failure. Curr Opin Cardiol. 1994;9(suppl 1):S2-S10.
2. Weber KT, Janicki JS, Pick R, Capasso J, Anversa P. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol. 1990;65:1G-7G.
3. d'Uscio L, Moreau P, Shaw S, Takase H, Barron M, Lüscher TF. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension. 1997;29:435-441.
4. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation. 1997;96: 1593-1597.
5. Hocher B, Thöne-Reineke C, Bauer C, Raschack M, Neumayer HH. The paracrine endothelin system; pathophysiology and implications in clinical medicine. Eur J Clin Chem Clin Biochem. 1997;35:175-189.
6. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiroi Y, Mizuno T, Maemura K, Kurihara H, Aikawa R, Takano H, Yazaki Y. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem. 1996;271:3221-3228.
7. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Murumo F, Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 1993;92:398-403.
8. Neyses L, Nouskas J, Luyken J, Fronhoffs S, Oberdorf S, Pfeifer U, Williams RS, Sukhatme VP, Vetter H. Induction of immediate-early genes by angiotensin II and endothelin-1 in adult rat cardiomyocytes. J Hypertens. 1993;11:927-934.
9. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Mace B, Comoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976-1982.
10. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 1993;27:2130-2134.
11. Pleissner KP, Regitz-Zagrosek V, Krüdewagen B, Trenkner J, Hocher B, Fleck E. Effects of renovascular hypertension on myocardial protein patterns: analysis by computer-assisted 2-dimensional gel electrophoresis. Electrophoresis. 1998;19:2043-2050.
12. Hocher B, Zart R, Diekmann F, Rohmeiss P, Distler A, Neumayer HH, Bauer C, Gross P. Paracrine renal endothelin system in rats with liver cirrhosis. Br J Pharmacol. 1996;118:220-227.
13. Hocher B, Liefeldt L, Thöne-Reineke C, Orzekowski HD, Distler A, Bauer C, Paul M. Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension. 1996;28: 196-201.
14. Lowry OH, Rosebrough LJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
15. Hocher B, Zart R, Schwarz A, Vogt V, Thöne-Reineke C, Braun N, Neumayer HH, Koppenhagen K, Rohmeiss P, Bauer C. Renal endothelin system in polycystic kidney disease. J Am Soc Nephrol. 1998;9: 1169-1177.
16. Hocher B, Thöne-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer HH, Schleuning WD, Theuring F. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis and renal cysts but not hypertension. J Clin Invest. 1997;99:1380-1389.
17. Oerning CH, Jalil JG, Janicki JS, Pick R, Aghili SH, Abrahams C, Weber KT. Collagen network remodelling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res. 1988;22: 686-695.
18. Brilla C, Matsubara L, Weber KT. Antihypertensive effects of spironolactone in myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;71:12A-16A.
19. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Murumo F, Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 1993;92:398-403.
20. Deng LY, Schiffrin EL. Endothelin-1 gene expression in blood vessels and kidney of spontaneously hypertensive rats (SHR), L-NAME-treated SHR, and renovascular hypertension. J Cardiovasc Pharmacol. 1998;31: S380-S383.
21. Li JS, Knafo L, Turgeon A, Garcia R, Schiffrin E. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol. 1996;271:H88-H93.
22. Brown JJ, Davies DL, Morton JJ, Robertson JI, Cuesta V, Lever AF, Padfield PL, Trust P. Mechanism of renal hypertension. Lancet. 1976;1: 1219-1221.
23. Melaragno MG, Fink GD. Enhanced slow pressor effect of angiotensin II in two-kidney one clip rats. Hypertension. 1995;25:288-293.
24. Ishiye M, Umemura K, Uematsu T, Nakashima M. Angiotensin ATN1 receptor-mediated attenuation of cardiac hypertrophy due to volume overload: involvement of endothelin. Eur J Pharmacol. 1995;280:11-17.
25. Thibault G, Arguin C, Garcia R. Cardiac endothelin-1 content and receptor subtype in spontaneously hypertensive rats. J Mol Cell Cardiol. 1995;27:2327-2336.
26. Ito H, Hiroe M, Hirata Y, Fujisaki H, Adachi S, Akimoto H, Ohta Y, Marumo F. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation. 1994;89: 2198-2203.
27. Clark KL, Pierre L. Characterization of endothelin receptors in rat renal artery in vitro. Br J Pharmacol. 1995;114:785-790.
28. Riezebos J, Watts IS, Vallance PJ. Endothelin receptors mediating functional responses in human small arteries and veins. Br J Pharmacol. 1994;111:609-615.
29. Katwa LC, Guarda E, Weber KT. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res. 1993;27:2125-2129.
30. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res. 1993;27:2130-2134.
31. Rebsamen MC, Church DJ, Morabito D, Vallotton MB, Lang U. Role of cAMP and calcium influx in endothelin-1-induced ANP release in rat cardiomyocyte. Am J Physiol. 1997;273:E922-E931.
32. Fujisaki H, Ito H, Hirata Y, Tanaka M, Hata M, Lin M, Adachi S, Akimoto H, Marumo F, Hiroe M. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest. 1995;96:1059-1065.
33. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Mace B, Comoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure: effects of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96:1976-1982.
34. Karam H, Heudes D, Hess P, Gonzales MF, Loffler BM, Clozel M, Clozel JP. Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. Cardiovasc Res. 1996; 31:287-295.
35. Schiffrin EL, Intengan HD, Thibault G, Touyz RM. Clinical significance of endothelin in cardiovascular disease. Curr Opin Cardiol. 1997;12: 354-367.
36. Ishida A, Sasaguri T, Kosaka C, Nojima H, Ogata J. Induction of the cyclin-dependent kinase inhibitor p21 (Sdil/Cip1/Waf1) by nitric oxide-generating vasodilatator in vascular smooth muscle cells. J Biol Chem. 1997;272:10050-10057.
37. Sarkar R, Gordon D, Tanley JC, Webb RC. Cell cycle effects of nitric oxide on vascular smooth muscle cells. Am J Physiol. 1997;272: H1810-H1818.
38. Etienne P, Pares Herbute N, Monnier L. Enhanced antiproliferative effects of nitric oxide in cultured smooth muscle cells from diabetic rats. J Cardiovasc Pharmacol. 1996;27:140-146.
39. Luft FC. Microalbuminuria and essential hypertension: renal and cardiovascular implications. Curr Opin Nephrol Hypertens. 1997;6:553-557.
40. Sihm I, Schroeder AP, Aalkjaer C, Holm M, Mom B, Mulvany M. Thygesen K, Lederballe O. Regression of media-to-lumen ratio of human subcutaneous arteries and left ventricular hypertrophy during treatment with an angiotensin-converting enzyme inhibitor-based regimen in hypertensive patients. Am J Cardiol. 1995 24;76:38E-40E.